Search Results
Nov 04, 2025, 01:37 ET Gateway Gulf 2025 Secures Over USD 17 billion in Announcements, Partnerships and Deals
year. Beyon Sovereign HyperCloud: Beyon Solutions, and the Information & eGovernment Authority (IGA), are set to launch Bahrain's first AI-ready Sovereign HyperCloud, powered by Oracle. Beyon Solutions:
More news about: Bahrain EDB
Nov 01, 2025, 12:39 ET LA WOMEN'S TENNIS ASSOCIATION CÉLÈBRE LE STYLE ET LA CULTURE MONDIALE AVEC LES PORTRAITS EMBLÉMATIQUES DE LA FINALE 2025 DE LA WTA
portaient des tenues de créateurs internationaux, dont Coco Gauff en Miu Miu, Jasmine Paolini en Brunello Cucinelli, Aryna Sabalenka en Alberta Ferretti, Iga Swiatek en Lurline (une marque saoudienne fondée par les sœurs Sarah et Siham Albinali), Taylor Townsend en Hervé Léger, Luisa Stefani en Altuzarra,
More news about: WTA
Nov 01, 2025, 12:37 ET WOMEN'S TENNIS ASSOCIATION FEIERT GLOBALEN STIL UND KULTUR MIT IKONISCHEN PORTRÄTS DER WTA-FINALS 2025
internationalen Designern, darunter Coco Gauff in einer Sonderanfertigung von Miu Miu, Jasmine Paolini in Brunello Cucinelli, Aryna Sabalenka in Alberta Ferretti, Iga Swiatek in einer Sonderanfertigung von Lurline (einer saudi-arabischen Marke, die von den Schwestern Sarah und Siham Albinali gegründet wurde), Taylor
More news about: WTA
Nov 01, 2025, 12:33 ET La WTA celebra el estilo y la cultura globales con retratos icónicos de las finales WTA 2025
internacionales, como Coco Gauff con un diseño exclusivo de Miu Miu, Jasmine Paolini con uno de Brunello Cucinelli, Aryna Sabalenka con uno de Alberta Ferretti, Iga Swiatek con un diseño a medida de Lurline (una marca saudí fundada por las hermanas Sarah y Siham Albinali), Taylor Townsend con uno de Hervé Léger,
More news about: WTA
Oct 31, 2025, 07:41 ET WOMEN'S TENNIS ASSOCIATION CELEBRATES GLOBAL STYLE AND CULTURE WITH ICONIC 2025 WTA FINALS PORTRAITS
range of international designers, including Coco Gauff in custom Miu Miu, Jasmine Paolini in Brunello Cucinelli, Aryna Sabalenka in Alberta Ferretti, Iga Swiatek in bespoke Lurline (a Saudi Arabian brand founded by sisters Sarah and Siham Albinali), Taylor Townsend in Hervé Léger, Luisa Stefani in Altuzarra,
More news about: WTA
Oct 31, 2025, 07:20 ET WOMEN'S TENNIS ASSOCIATION CELEBRATES GLOBAL STYLE AND CULTURE WITH ICONIC 2025 WTA FINALS PORTRAITS
range of international designers, including Coco Gauff in custom Miu Miu, Jasmine Paolini in Brunello Cucinelli, Aryna Sabalenka in Alberta Ferretti, Iga Swiatek in bespoke Lurline (a Saudi Arabian brand founded by sisters Sarah and Siham Albinali), Taylor Townsend in Hervé Léger, Luisa Stefani in Altuzarra,
More news about: WTA
Oct 29, 2025, 09:00 ET Bernard Gavgani, Former Global CIO of BNP Paribas, Joins 1touch.io Board of Directors to Advance AI-Driven Data Security
compliance workload through automated evidence and context-rich reporting. 1touch.io seamlessly integrates with SIEM, DLP, IAM/IGA, cloud, and workflow platforms, extending the value of existing security investments. Its technology also powers IBM Guardium Discover and Classify
More news about: 1touch.io
Oct 28, 2025, 08:46 ET PromoRepublic Launches the First-in-Category Mobile AI Assistant for Local Marketing
for multi-location and franchise brands. Trusted by over 110 enterprise and franchise networks — including Empower Brands, Threshold Brands, Metcash/IGA Supermarkets, and Expedia Cruises — PromoRepublic helps distributed brands orchestrate and measure local marketing performance. The
More news about: PromoRepublic
Oct 27, 2025, 10:20 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
renal indications with significant unmet medical need. The Company's lead programme, PS-002, offers a highly differentiated approach for patients with IgA nephropathy (IgAN). By precisely targeting the site of disease, Purespring aims to transform the trajectory of kidney disease so patients can live fuller,
More news about: CHROMATIN BIOSCIENCE LTD
Oct 27, 2025, 10:15 ET Chromatin Bioscience Announces Collaboration with Purespring Therapeutics
renal indications with significant unmet medical need. The Company's lead programme, PS-002, offers a highly differentiated approach for patients with IgA nephropathy (IgAN). By precisely targeting the site of disease, Purespring aims to transform the trajectory of kidney disease so patients can live fuller,
More news about: CHROMATIN BIOSCIENCE LTD
Oct 24, 2025, 08:00 ET Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
72% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) 0/1 score and 57% achieved ss-IGA 0b 85% of patients with genital psoriasis achieved a Physician's Global Assessment of Genitalia
More news about: Johnson & Johnson
Oct 24, 2025, 06:45 ET Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
62% of patients taking EBGLYSS once every other month and 73% of patients taking EBGLYSS monthly, respectively, achieved or maintained IGA 0,1. There was no increased risk of immunogenicity (the production of anti-drug-antibodies), and no new safety findings. These
More news about: Eli Lilly and Company
Oct 24, 2025, 04:00 ET Renalys Pharma to be Acquired by Chugai Pharmaceutical
burden on the Japanese healthcare system. IgA nephropathy is widely known as one of the main causes of kidney failure and is considered to develop when abnormal IgA proteins are deposited in kidney tissue, inhibiting kidney function and causing inflammation. IgA nephropathy is a rare intractable disease
More news about: Renalys Pharma, Inc.
Oct 22, 2025, 17:31 ET Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
IgA Nephropathy Market IgA Nephropathy Market Insight, Epidemiology, and Market Forecast – 2034 report
More news about: DelveInsight Business Research, LLP
Oct 17, 2025, 02:00 ET Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)
evaluable patients in the Phase Ⅲ clinical trial of IgA nephropathy, with topline results expected in Q4 2025. In 2024, Travere received full FDA approval for sparsentan (U.S. brand name: FILSPARI®) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression*.
More news about: Renalys Pharma, Inc.
Oct 15, 2025, 16:30 ET Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region
which includes Effexor for the treatment of generalized anxiety disorder (GAD) which is under regulatory review, selatogrel in Acute MI, Nefecon in IgA nephropathy, and cenerimod in systemic lupus erythematosus (SLE), all of which have pivotal Phase 3 trials currently on going and Tyrvaya in dry eye
More news about: Viatris Inc.
Oct 15, 2025, 09:00 ET GC Biopharma Announces Symposium on Clinical and Patient Experience in Primary Immunodeficiency and Poster Presentations on IVIG Manufacturing and Viscosity at the 2025 IgNS Annual Meeting
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Hypersensitivity: In case of hypersensitivity,
More news about: GC Biopharma USA Inc.
Oct 14, 2025, 01:40 ET 2025 ACR Abstract Released! Exciting Data from Telitacicept's Phase III Clinical Study in Sjögren's Syndrome in China
consistent with prior studies across other autoimmune indications, including systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, and IgA nephropathy. No new safety signals were observed. Most adverse events were mild to moderate in severity. Sjögren's
More news about: RemeGen Co., Ltd
Oct 13, 2025, 09:00 ET GC Biopharma Highlights IVIG Innovation and Investigator-Initiated Research as Science to Solutions Partner at the Fall 2025 CIIC Conference
in patients who have a history of anaphylactic or severe systemic reaction to the administration of human immune globulin and in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Hypersensitivity: In case of hypersensitivity,
More news about: GC Biopharma USA Inc.
Oct 10, 2025, 10:00 ET Pathlock Recognized in the 2025 Gartner® Market Guide for Identity Governance and Administration
and administration (IGA) as "the solution to manage the identity life cycle and govern access across on-premises and cloud environments." Gartner notes "The IGA market worldwide grew 9.2% from 2023 to 2024, with forecast 2024 to 2025 growth of 10.7%, as of 2Q25. The IGA market's growth is increasingly
More news about: Pathlock
Oct 10, 2025, 02:00 ET Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan
standard EU approval for the IgA nephropathy indication in 2025. *FILSPARI® (sparsentan) U.S. Indication: FILSPARI is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline in adults with primary IgA nephropathy who are at
More news about: Renalys Pharma, Inc.
Oct 09, 2025, 10:00 ET Omada Named "Overall ID Management Solution Provider of the Year" in 9th Annual CyberSecurity Breakthrough Awards Program
About OmadaOmada, a global market leader in Identity Governance and Administration (IGA), offers a full-featured, enterprise-grade, cloud native IGA solution that enables organizations to achieve compliance, reduce risk, and maximize efficiency. Founded in 2000, Omada
More news about: Omada
Oct 08, 2025, 08:03 ET Omada Named a Representative Vendor in the 2025 Gartner® Market Guide for Identity Governance and Administration
business drivers, leading to a variety of offered IAM features. This research helps IAM leaders navigate the IGA market and improve decision making." Omada's modern IGA solutions, Omada Identity and Omada Identity Cloud, deliver essential
More news about: Omada
Oct 08, 2025, 08:00 ET SecurEnds Launches Redesigned SMART IGA Platform to Revolutionize Enterprise Identity Governance
SecurEnds today announced the redesigned SMART IGA platform, featuring advanced Access Analysis, Access Templates, and T-Hub powered Provisioning and Deprovisioning. The update delivers smarter analytics,
More news about: SecurEnds
Oct 07, 2025, 09:00 ET Century Health and Balboa Nephrology Partner to Unlock AI-Driven Insights for Clinical Research and Drug Development in Chronic Kidney Diseases
Together, Century Health and Balboa Nephrology will combine clinical expertise with AI to improve care and accelerate treatments in conditions such as IgA nephropathy, lupus nephritis, and C3 glomerulonephritis
More news about: Century Health